You are here: Industry Insights > Dermatitis

News List

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis PharmaSources
January 17, 2024
InnoCare Pharma announced today that phase II clinical study results of novel TYK2 inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis.
FDA Approves Rinvoq for Treatment of Atopic Dermatitis drugs.com
January 19, 2022
The U.S. Food and Drug Administration approved Rinvoq (upadacitinib) for the treatment of moderate-to-severe...
Sanofi unveils new data for Dupixent in children with dermatitis pharmatimes
April 03, 2020
Sanofi has unveiled more detailed late-stage data showing the benefit of biologic Dupixent (dupilumab) in a population of young patients with uncontrolled severe atopic dermatitis.
Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials pharmaceutical-business-review
December 16, 2019
Danish medical dermatology firm Leo Pharma announced that its tralokinumab has achieved all primary and secondary endpoints in three phase 3 studies for the treatment of adults ...
ASLAN Pharmaceuticals acquires rights to atopic dermatitis asset pharmaceutical-technology
June 05, 2019
ASLAN Pharmaceuticals has amended its licensing agreement with CSL to obtain complete worldwide rights to develop, manufacture and commercialise fully human monoclonal antibody (mAb) ASLAN004 across all indications.
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis drugs
May 20, 2019
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis.
Investigational cream could help patients with atopic dermatitis europeanpharmaceuticalreview
April 16, 2019
A Phase IIb double-blind trial has shown the success of the topical cream PAC‐14028 for the treatment of atopic dermatitis…
Severe eczema may best be treated by allergy shots: Significant benefits seen in one medically challenging case firstwordpharma
November 19, 2018
A medically-challenging case being presented at the American College of Allergy, Asthma and Immunology (ACAAI) conference found that allergy injections provided
GSK sells psoriasis/dermatitis therapy to Dermavant pharmatimes
July 13, 2018
GlaxoSmithKline has sold rights to an experimental therapy with potential in psoriasis and dermatitis to Dermavant in a deal worth $330 million.
Upadacitinib receives breakthrough therapy designation for atopic dermatitis europeanpharmaceuticalreview
January 10, 2018
Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018…